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Abstract
Background: Neisseria meningitidis colonizes humans and transmits mainly by asymptomatic carriage. We sought to
determine the prevalence and epidemiology of meningococcal carriage in Ethiopia prior to the introduction of
MenAfriVac, a serogroup A meningococcal conjugate vaccine.
Methods: A cross-sectional meningococcal carriage study was conducted in Arba Minch, southern Ethiopia. A total
of 7479 oropharyngeal samples were collected from 1 to 29 year old volunteers, between March and October,
2014. The swabs were cultured for N. meningitidis and Neisseria lactamica in Ethiopia. N. meningitidis isolates were
confirmed and characterized by their serogroup, sequence type (ST) and PorA:FetA profile in Norway.
Results: Overall carriage prevalence was 6.6 %. There was no significant difference in overall carriage between male
(6.7 %) and female (6.4 %) participants. Highest carriage prevalence (10.9 %) for females was found in the 15–19
years of age, while prevalence among males was highest (11.3 %) in the 20–24 age group. Non-groupable isolates
dominated (76.4 %), followed by serogroups X (14.0 %) and W (5.9 %) isolates. No serogroup A was found. Most
non-groupable isolates were ST-192. Serogroup W isolates were assigned to the ST-11 clonal complex, and serogroup X
isolates to the ST-181 and ST-41/44 clonal complexes. Overall carriage prevalence of N. lactamica was 28.1 %. Carriage of
N. meningitidis and N. lactamica varied depending on age and geographic area, but there was no association between
carriage of the two species.
Conclusions: Epidemic strains of serogroups W and X were circulating in this area of Ethiopia. As no serogroup A was
found among the carriage isolates the immediate impact of mass-vaccination with MenAfriVac on transmission of
N. meningitidis in this population is expected to be marginal.
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Background
Neisseria meningitidis, the meningococcus, is a com-
mensal microorganism colonizing the upper respiratory
tract, usually without causing disease. Meningococci are
found only in humans and the bacterium is transmitted
mainly through close contact and airborne droplets.
Carriage prevalence varies geographically, but is usually
around 5–10 % [1, 2]. However, in crowded or contained
societies, such as universities, carriage prevalence can be
significantly higher [3, 4]. Carriage prevalence is usually
found to be higher in males than females. In Europe and
USA, carriage prevalence is low during childhood and
peaks in the adolescence, while carriage is more com-
mon among younger children in Africa [5]. Living condi-
tions and social behavior, such as active and passive
smoking [6], discotheque visits and crowding [7], are
among the known risk factors for carriage.
Occasionally, the bacteria can invade the bloodstream
and reach the spinal fluid, and rapidly cause meningitis
and/or septicemia [8, 9]. Of 12 known capsular ser-
ogroups, serogroups A, B, C, W, X and Y are responsible
for nearly all cases of disease. Meningococcal disease oc-
curs endemically throughout the world, but in a region
designated as the meningitis belt in sub-Saharan Africa,
outbreaks and epidemics occurs every year in the dry
season. During these epidemics, carriage prevalence of
the outbreak strain can increase by a factor of 10 or
higher [10].
Molecular characterization of N. meningitidis is per-
formed by multilocus sequence typing (MLST), which
assigns isolates to a sequence type (ST) and eventually
to a clonal complex, based on the allelic variation in
seven housekeeping genes. Classification of variable re-
gions in two outer membrane proteins, PorA and FetA,
is also commonly used for additional characterization. In
the meningitis belt, serogroup A meningococci of the
ST-5 clonal complex have caused most of the epidemics
during the past 4 decades [11, 12]. More recently,
serogroup X ST-181 and serogroup W ST-11 have also
caused large epidemics [13–16], and currently a new
serogroup C clone assigned to ST-10217 is spreading in
the meningitis belt [17].
Neisseria lactamica is a non-pathogenic, closely re-
lated species that share the same ecological niche as N.
meningitidis. Carriers of N. lactamica develop cross-
reacting systemic opsonophagocytic antibodies to N.
meningitidis [18] and natural immunity against the
meningococci may result from carriage of these closely
related commensals. Several epidemiological studies
have shown an inverse relationship between carriage of
N. lactamica and meningococci [19–21]. It has been
suggested that carriage of N. lactamica can inhibit
meningococcal carriage [22, 23] and a recent study has
shown that inoculation of N. lactamica in the oropharynx
can both displace current carriage and protect against
new acquisition of N. meningitidis [22].
As meningococci are transmitted by healthy carriers,
conjugated vaccines that prevent colonization, in addition
to protecting vaccinated individuals against invasive
disease, have shown to be very efficient to control disease
[24]. In 2010, a new meningococcal conjugate vaccine, de-
veloped specifically for the sub-Saharan meningitis belt,
was introduced. The vaccine, MenAfriVac, contains 10 μg
serogroup A polysaccharide conjugated to tetanus toxoid,
and has been introduced in mass vaccination campaigns
of all 1–29 year olds in more than 15 countries. In
Ethiopia, one of the countries with high epidemic risk and
high disease burden, vaccination has been implemented in
3 phases from 2013 to 2015 [25]. Prior to and in relation
to the implementation of the vaccine, several carriage
studies have been conducted across the meningitis belt,
showing the vaccine’s ability to prevent carriage, and
giving useful information about which serogroups and
clones that circulate [5, 26–28]. Butajira, in central
Ethiopia, was part of one of the carriage studies in the
period 2010–2012. Carriage prevalences from 4.3 to
10.0 % were reported [5]. The majority of the isolates were
non-groupable (NG), but isolates of serogroup B, C, W, X
and Y were also identified [5]. Surveillance of invasive
meningitis isolates in Ethiopia in 2012-2013 showed, on
the other hand, that in Hawassa, in the southern part of
the country, serogroup A was the dominant cause of
disease [29].
Therefore, to better understand the epidemiology of
meningococcal carriage in southern Ethiopia and to pre-
dict the potential impact of MenAfriVac, we conducted
a carriage study in advance of the introduction of the
vaccine. The results from this carriage study are pre-
sented here, together with data on N. lactamica carriage,
as only a few such studies have been done in sub-
Saharan Africa [30–32].
Methods
Study design and sampling
A cross-sectional carriage study was conducted among
healthy volunteers aged 1–29 years in the district of
Arba Minch in southern Ethiopia during the rainy sea-
son, between March 18th and October 1st, 2014. Four
kebeles (the smallest administrative unit within a district)
were included; Genta Mechie (A), Zigiti Mechie (B), Gatse
(C) and Kolla Shelle (D) (Fig. 1). These are all part of the
national, community-based Demographic Surveillance
System (DSS) in Ethiopia.
Community leaders were consulted and informed about
the study prior to sampling. All individuals between 1 and
29 years were invited to participate and recruitment was
done by data collectors from the DSS. Demographic data
on age and gender were obtained from each participant,
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together with consent for participation, information re-
garding meningococcal vaccination in the last 5 years and
antibiotic use within the last 30 days.
Sampling took place at open-aired squares or fields
centrally located in each village. Oropharyngeal samples
were obtained by swabbing the posterior pharyngeal wall
and one tonsil with a plain cotton swab (Copan, Italy).
Swabs were plated directly onto selective agar plates
containing vancomycin, colistin, nystatin, trimethoprim
lactate (VCNT, Becton, Dickinson, NJ, US) and Vitox
supplement (Thermo Fisher Scientific, MA, US) in the
field, before being transported in CO2-enriched con-
tainers, at ambient temperature, to the microbiology la-
boratory at Arba Minch General Hospital within 6 h, for
incubation at 37 °C overnight.
Laboratory analysis
Identification of N. meningitidis and N. lactamica was
made by examination of colony morphology on the
VCNT plates, subculture on blood agar plates, oxidase
reaction, Gram staining and enzymatic testing for β-
galactosidase (ONPG) and γ-glutamyltransferase (GGT)
[33]. N. meningitidis isolates were serogrouped by con-
ventional slide agglutination (Remel, GA, USA). The
meningococcal strains were stored in Greaves solution
[34] at −80 °C, and transported on dry ice for confirma-
tory re-analysis and further characterization using mo-
lecular methods at the Norwegian Institute of Public
Health (NIPH).
According to a previously established quality control
scheme [35], randomly chosen non-meningococcal isolates
were used as external quality control samples. These
were collected during the identification process, both at
the stage of colony morphology and at the stage of en-
zymatic testing, and were re-analyzed at NIPH. The
final results on meningococcal carriage, including mo-
lecular characterization, were based on confirmed re-
sults from NIPH only.
Molecular characterization
DNA from the isolates was extracted by suspension in
Tris-ethylenediaminetetraacetic acid (EDTA) buffer
(10 mM Tris-HCl and 1 mM EDTA), pH 8.0, heating at
95 °C for 10 min and centrifugation at 16,000 × g for
5 min. DNA from the supernatant was amplified by
PCR, and MLST was performed according to the
method on the website (http://pubmlst.org/neisseria/)
[36]. Classification by outer membrane protein PorA
and FetA variants was done by sequencing of the porA
[37] and fetA [38] genes. New MLST alleles, STs, PorA
and FetA variants were submitted to the MLST database.
PCR analysis of capsule coding genes was undertaken
for serogroup determination of isolates with question-
able slide agglutination results. Isolates assigned to new
STs and a subset of isolates assigned to the ST-53 and
ST-192 clonal complexes, known to harbor the cnl locus
[39], were also included in capsule PCR analysis.
Phylogeny
The concatenated sequences from the MLST analysis
were aligned with MAFFT [40] and non-informative sites
were removed prior to phylogenetic analyses. Maximum
Fig. 1 Location of study sites in Ethiopia. (Map created using ArcMAP 10.3.1)
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likelihood (ML) estimation was subsequently performed
to estimate the optimal nucleotide substitution matrix by
the PhyML program [41] within the R-package “Ape” [42].
The generalized time reversible (GTR) substitution matrix
was found to be optimal as assessed with the Akaike infor-
mation criterion and used with the RAxML program [43]
to create a ML-tree. The tree was bootstrapped 500 times.
Data management and statistical analyses
Demographic data from participants and laboratory re-
sults were merged in a Microsoft Access database at the
NIPH. Samples without complete traceability were ex-
cluded from the analysis.
Data examination and creation of tables and graphs
were performed using Microsoft Excel 2010. Compari-
son of prevalence between groups was done with a chi-
square test in IBM SPSS Statistics 23 statistical software.
Remaining statistical analyses were performed using the
statistical programming language R [44]. A p-value <0.05
was considered statistically significant.
To study factors affecting carriage, a proportional bi-
nomial generalized additive regression model (GAM)
[45] was fitted with the number of N. meningitidis posi-
tives and negatives for each age i = 1–29 as the response.
Sex (male/female) and kebele (A, B, C and D) were
added as categorical covariates and age was fitted with a
spline function f():
yieBin ni; πið Þ
logit πið Þ
e
β0 þ f Ageið Þ þ β1Sexi þ β2Kebelei
where yi is the number of positives for each age i, πi is
the probability of being infected and ni is the number of
samples. Goodness of fit was assessed by R2 (GAM) and
using the Akaike information criterion.
Simpson’s Index of Diversity was calculated based on
serogroup, ST-complex, STs, PorA and FetA variants to
determine the diversity of the meningococcal isolates by
kebele. The index ranges from 0 to 1, with higher values
indicating greater diversity, and was calculated as des-
cribed previously [46].
Results
Study population and samples
A total of 7722 individuals from 4 different kebeles
was enrolled in the study and complete linked partici-
pant information was obtained for 7479 (96.8 %), who
were then included in the analyses (Table 1). There
was an equal participation of males (n = 3740) and fe-
males (n = 3739). Age ranged from 1 to 29 years and
the majority of the participants, 58.1 %, were below
10 years of age. The average and median ages were
11.0 and 9.0 years for females, slightly older than for
males, which were 9.3 and 8.0 years, respectively.
None of participants in kebeles A, B and C reported
to have been vaccinated with any meningococcal vac-
cine in the last 5 years, whereas 5.6 % of the partici-
pants (n = 86) in kebele D had been vaccinated with a
meningococcal A + C polysaccharide vaccine in a reactive
mass vaccination campaign by Ethiopian health authorities
following an epidemic in 2013. Except for 2 participants in
kebele D, no others reported the use of antibiotics in
the last 30 days prior to sampling.
Laboratory quality control
To ensure correct estimation of carriage prevalence, 5 %
of all primary samples assessed to be non-meningococcal
at the laboratory in Arba Minch were stored for external
quality control. These samples were re-analyzed at NIPH
and none were identified as meningococci. Of 591 isolates
identified as N. meningitidis in Arba Minch, 492 isolates
were confirmed as such at NIPH (83.2 %). The final results
on meningococcal carriage were based on confirmed re-
sults from NIPH, leaving no false negative or false positive
meningococcal samples in the data analyses.
Table 1 Demographic data of study participants, in percent
Kebelea
Total A B C D
(n = 7479) (n = 1307) (n = 2479) (n = 2161) (n = 1532)
Gender Male 50.0 50.7 51.3 50.1 47.3
Female 50.0 49.3 48.7 49.9 52.7
Age 1–4 21.1 16.7 22.7 23.3 19.0
5–9 37.0 33.4 40.9 35.1 36.4
10–14 22.4 26.4 23.5 19.8 20.9
15–19 6.6 9.3 5.6 4.3 8.9
20–24 4.4 4.6 3.0 4.1 7.0
25–29 8.6 9.6 4.4 13.4 7.8
aKebele: Genta Mechie (A), Zigiti Mechie (B), Gatse (C) and Kolla Shelle (D)
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Meningococcal carriage epidemiology
Overall carriage prevalence was 6.6 %. Prevalence ranged
from 3.2 % in kebele D to 9.9 % in kebele C, varying sig-
nificantly between the different kebeles (Fig. 2, Table 2).
There was no overall significant difference in carriage
between male (6.7 %) and female (6.4 %) participants
(Fig. 3, Table 2). Carriage incidence varied by age (Fig. 4,
Table 2) and the overall peak prevalence was seen in the
16 year olds. For females, the highest carriage prevalence
(10.9 %) was found in the 15–19 years of age, while
among males, prevalence was highest (11.3 %) in the
20–24 age group (Fig. 4).
Carriage prevalence among individuals from kebele D
who were vaccinated with a meningococcal A + C poly-
saccharide vaccine in 2013 was higher (5.8 %, n = 5/86)
than among those who were not vaccinated (3.0 %, n =
44/1446), but the difference was not statistically signifi-
cant, confirming that polysaccharide vaccines have no
long term, if any, impact on carriage [47]. Among those
previously vaccinated, 2 were carriers of serogroup C
and 3 of NG meningococci.
We identified a total of 376 NG isolates, which repre-
sented 76.4 % of all isolates, and a carriage prevalence of
NG meningococci of 5.0 %. Among the encapsulated
isolates, serogroup X dominated with a prevalence of
0.9 %, followed by serogroups W, Y, C and B (Table 3).
None of the isolates were assigned to serogroup A.
The serogroup distribution varied between the 4
kebeles (Fig. 5). Serogroup W, X, Y and NG isolates were
found in all kebeles, whereas the less frequent ser-
ogroups, serogroup C and serogroup B were found only
in kebeles A, C and D, or kebeles C and D, respectively.
Kebeles A, B and C, which are connected to each other
and to Arba Minch city by the same road (Fig. 1), had
the highest proportions of NG isolates (Fig. 5). On this
same geographical axis, the proportion of W isolates
declined with increasing distance from the city, from
11.5 % in kebele A, to 6.4 % and 3.3 % in kebeles B and
C, respectively. The proportion of serogroup X isolates,
on the other hand, increased with the distance from the
city: 1.9 %, 11.2 % and 16.8 % in kebeles A, B and C, re-
spectively. In kebele D, the distribution was different;
the proportion of NG isolates were lower (46.9 %) and
there was a higher proportion of serogroup X and C iso-
lates (36.7 % and 8.2 %, respectively).
Molecular characterization
The strain collection was composed of a total of 32 STs;
25 STs belonging to 11 different clonal complexes, and 7
STs unassigned to a clonal complex (Table 4). Among
the 492 meningococcal isolates, we identified 8 new al-
leles, 13 new STs, 4 new PorA variants and 4 new FetA
variants. All new STs and alleles were submitted to the
pubMLST website [48].
The majority of isolates (57.8 %, n = 284) was assigned
to ST-192, with PorA variant P1.18-11,42-1, and lacking
FetA. All of these isolates were NG (Table 4) and, thus,
carriage prevalence of this specific clone was 3.8 %. Two
isolates were single-locus variants of ST-192 and were,
together with a subset of 147 ST-192 isolates (52 %),
subjected to PCR of the capsule locus; all of them har-
bored the cnl locus. All 50 NG isolates belonging to the
ST-53 clonal complex were also capsule null (Table 4),
as was a cluster of NG isolates closely related to ST-
11587.
The majority of serogroup X isolates were assigned to
the ST-181 clonal complex, being either ST-181 (n = 7),
ST-11372 (n = 48) or ST-11591 (n = 6) (Table 4). Seven
serogroup X isolates were assigned to ST-207 of the ST-
41/44 clonal complex; all had the same PorA variant, but
4 different FetA variants were identified.
All 29 serogroup W isolates were assigned to ST-11
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Fig. 2 Carriage prevalence of N. meningitidis and N. lactamica, in total and by kebele, in Arba Minch, Southern Ethiopia
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assigned to the hypervirulent ST-11 clone, known to
cause large epidemics [49].
Of the 7 serogroup C isolates, five were assigned to
the ST-11592, a new ST of the ST-103 complex (Table 4).
Only 2 serogroup B isolates were identified, both assigned
to the ST-35 clonal complex. The 9 serogroup Y isolates
belonged to the ST-167 complex.
The most frequent STs were found in all kebeles, except
ST-53 which was found in kebele B and C only. All STs
represented by 5 or more isolates were present in more
than one kebele. The majority of the 16 STs found only in
one kebele were new STs (n = 13) and were found mostly
in kebele C (n = 10). Isolates from kebele C are spread
across the phylogenetic tree, while isolates from the other
kebeles are more clustered in the centre and lower part of
the tree (Fig. 6). The diversity of meningococcal isolates
varied between kebeles and kebele C had the highest num-
ber of STs (n = 24) and genotypes, defined as unique ST
and PorA/FetA combinations (n = 41) (Fig. 6, Table 4).
Simpson’s Index of Diversity, ranging from least to most
diverse, was estimated to 0.433 for kebele A, 0.610 for
kebele B, 0.679 for kebele C and 0.880 for kebele D.
Table 2 Factors affecting carriage of Neisseria meningitidis and Neisseria lactamica in Arba Minch, Southern Ethiopia
Neisseria meningitidis Neisseria lactamica
Covariate Estimate 95 % CI P Estimate 95 % CI P
Sexa 0.06 (−0.13, 0.25) 0.536 0.04 (−0.06, 0.15) 0.439
Kebeleb A
B −0.41 (−0.68, −0.14) 0.001 0.37 (0.20, 0.53) <0.001
C 0.28 (0.03, 0.52) 0.028 0.42 (0.25, 0.60) <0.001
D −0.95 (−0.60, −1.30) <0.001 1.01 (0.84, 1.19) <0.001
Smooth term age edfc X2 P edf X2 P
f(Age) 2.31 14.78 0.002 3.54 178 <0.001
Goodness of fit R2 Deviance explained R2 Deviance explained
0.27 29.2 % 0.64 59.6 %
aMale used as reference
bKebele A used as reference




























Gender and age group
NG Serogroup Y Serogroup X Serogroup W Serogroup C Serogroup B Mean
Fig. 3 Meningococcal carriage prevalence by gender, age and serogroup in Arba Minch, Southern Ethiopia. (NG, non-groupable)
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Carriage of N. lactamica
Results from morphological and enzymatic testing per-
formed in Arba Minch were used to estimate the carriage
prevalence of N. lactamica (oxidase-positive, ONPG-
positive and GGT-negative isolates). Overall prevalence
was 28.1 %, with significant differences between the 4
kebeles (Table 2), ranging from 18.9 % in kebele A to
39.4 % in kebele D (Fig. 2). N. lactamica carriage varied
with age (Fig. 4, Table 2). The highest prevalence was seen
in 1 year old children (54.5 %) and declined until the age
of 16 years (20.2 %), when carriage increased again for
females while staying low for males. However, there was
no statistical difference in overall N. lactamica carriage
between females (27.6 %) and males (28.5 %) (Table 2).
The ratio between carriage of N. lactamica and N.
meningitidis varied from 0.42 in kebele A to 0.08 in
kebele D and there was no statistically significant asso-
ciation between carriage of N. lactamica and N. menin-
gitidis. There was no difference in carriage prevalence
of N. lactamica between those who had been vacci-
nated with a meningococcal A + C vaccine and those
who had not in kebele D (p = 0.61).
Discussion
We present here the epidemiology and molecular
characterization of meningococcal carriage isolates re-
trieved from 7479 children and young adults living in
southern Ethiopia, immediately before the introduction
of MenAfriVac. Carriage prevalence was 6.6 % and NG
meningococcal isolates dominated. No serogroup A iso-
lates were detected, but clones of other encapsulated
meningococci with epidemic potential circulated: serogroup
W ST-11 and serogroup X ST-181.
Despite the study being performed in the southern
part of Ethiopia where serogroup A disease had been re-
ported recently [29], no carriage of serogroup A was
found. This absence of serogroup A meningococci in
Ethiopia, as well as the low carriage prevalence of sero-
group A meningococci in several other countries across
the meningitis belt, was also shown in another recent
study [5]. The introduction of the monovalent serogroup
A conjugate vaccine is thus expected to have very limi-
ted measurable impact on transmission of the pathogen
Fig. 4 Absolute (bars) and percent (dotted trend line) carriage of N. meningitidis and N. lactamica carriage by age in Arba Minch, Southern Ethiopia
Table 3 Carriage of Neisseria meningitidis among 7479 individuals,
1–29 year old, in 4 kebeles in Arba Minch, Southern Ethiopia
Kebelea
Total A B C D
n % n % n % n % n %
Total 492 6.58 104 7.96 125 5.04 214 9.90 49 3.20
Serogroup B 2 0.03 0 0.00 0 0.00 1 0.05 1 0.07
Serogroup C 7 0.09 1 0.08 0 0.00 2 0.09 4 0.26
Serogroup W 29 0.39 12 0.92 8 0.32 7 0.32 2 0.13
Serogroup X 69 0.92 2 0.15 14 0.56 35 1.62 18 1.17
Serogroup Y 9 0.12 3 0.23 3 0.12 2 0.09 1 0.07
Non-groupable 376 5.03 86 6.58 100 4.03 167 7.73 23 1.50
aKebele: Genta Mechie (A), Zigiti Mechie (B), Gatse (C) and Kolla Shelle (D)
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and prevalence of meningococcal disease. Therefore, the
implementation of MenAfriVac in Ethiopia might not
have an immediate public health impact, as strains with
epidemic potential of other serogroups are currently cir-
culating in the population.
The meningococcal carriage prevalence was comparable
to that found in other studies in the region [2, 5, 50].
Overall, the serogroup distribution was consistent with re-
sults obtained by others during the rainy season in Buta-
jira, situated north of Arba Minch [5], although there was
a lower proportion of carriers with serogroup Y and a
higher proportion of carriers with serogroup X in our
study. The circulation of meningococcal strains with the
potential to cause large outbreak, such as ST-11 and ST-
181, is of concern, and the data from this study contribute
to inform the Ethiopian health authorities of what can be
expected in case of increasing incidence of meningococcal
disease. Serogroup W ST-11 is the dominating pathogenic
clone in most of the meningitis belt countries after ser-
ogroup A disease was practically eliminated following
mass vaccination with MenAfriVac. Serogroup X ST-181
has also shown potential for causing large outbreaks and
to date there is no available vaccine protecting against this
serogroup. One of the new STs identified in this study,
ST-11592 (serogroup C) was also identified among pa-
tients in East-Ethiopia in November 2015 (unpublished
data). This serogroup C genotype is not related to the epi-
demic clone ST-10217 currently spreading serogroup C
disease in Nigeria and Niger [17] and its epidemic po-
tential is unknown.
The high carriage prevalence of non-groupable menin-
gococci proves that the bacterial capsule is not a re-
quirement for person-to-person transmission. Although
large epidemics are caused by encapsulated bacteria,
non-groupable meningococci are also capable of causing
invasive disease [51–53].
The study shows that there are geographic variations
in both prevalence and serogroup distribution, even
within a small area. Kebele D differed most from the
other three sites with a significantly lower prevalence of
N. meningitidis and a higher proportion of encapsulated
bacteria. Kebele D is situated in the low land and is
more urbanized than the other three sites. The other
study sites are all in the highlands, with different tem-
perature and climatic conditions, and are situated along
the same road starting in Arba Minch city. Interestingly,
the prevalence of serogroup W decreased with the dis-
tance from the city, suggesting that this serogroup was
spreading from there, while the opposite was found for
serogroup X. The most frequent STs were found in all
study areas, and with one exception (ST-11372), all the
new STs discovered in this study were found only in one
or two kebeles. The majority of the new STs were found
in kebele C, the kebele which is situated furthest away
from the city of Arba Minch. This was also the kebele
with the highest carriage prevalence and the highest
diversity of meningococcal isolates. These observations
indicate that new STs emerge locally and, in the absence
of large epidemics, meningococcal carriage epidemiology
shows greater local variation.
Despite identifying more than 30 different STs among
the carriage strains, the diversity of the strain collection
was relatively low, as 85 % of the isolates were assigned
to one of 4 STs, and 97 % belonged to one of 19 STs.
However, the diversity was higher than reported from
























NG Serogroup Y Serogroup X Serogroup W Serogroup C Serogroup B
Fig. 5 Distribution of meningococcal serogroups by kebele in Arba Minch, Southern Ethiopia. (NG, non-groupable)
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Table 4 Molecular characteristics of meningococcal carriage isolates in 4 kebeles in Arba Minch, Southern Ethiopia
Sero-group ST-complex ST PorA FetA n Kebelea
A B C D
B 35 35 P1.22-1,14 F4-1 1 1
10450 P1.22-1,14 F4-1 1 1
C 103 11592 P1.5-1,10-4 F3-9 5 2 3
35 35 P1.22-1,14 F4-1 1 1
175 8447 P1.5-1,2-2 F5-8 1 1
W 11 11 P1.5,2 F1-1 26 12 7 5 2
F1-7 1 1
2724 P1.5,2 F1-1 1 1
7849 P1.5,2 F1-1 1 1
X 181 181 P1.5-1,10-1 F3-22 4 4
P1.5-1,10-1 F1-7 2 2
P1.5-1,10-1 F4-23 1 1
11372 P1.5-1,10-1 F4-23 48 2 12 21 13
11591 P1.5-1,10-1 F4-23 6 1 5




1053 P1.12-1,13-2 F5-169 1 1
Y 167 2880 P1.5-1,10-1 F1-3 8 3 3 1 1
767 P1.5-1,10-1 F1-3 1 1
NG 167 2880 P1.5-1,10-8 F1-3 9 1 2 5 1
175 175 P1.22-11,15-25 F5-1 1 1
P1.22-11,15-56 F5-1 3 3
8447 P1.5-1,2-2 F5-8 1 1
178 178 P1.19,15 F5-8 1 1
181 11372 P1.5-1,10-1 F4-23 1 1
192 192 P1.18-11,42-1 Neg 284 79 77 118 10
11598 P1.18-11,42-1 Neg 1 1
11642 P1.18-11,42-1 Neg 1 1
198 198 P1.18,25-11 F5-5 3 2 1
P1.25-11,38-1 F5-5 1 1
11741 P1.18,25-37 F1-7 1 1
P1.18,25-65 F1-7 2 1 1
35 35 P1.22-1,14 F4-1 4 1 3
53 53 P1.7,3 F1-7 2 2
P1.7,30 F1-3 2 2
F1-49 1 1
F1-7 7 2 5
F3-69 1 1
P1.7,30-2 F1-215 1 1
F1-7 4 1 3
F2-28 1 1
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previously been observed, that the diversity is higher in
countries on the edges of the meningitis belt, as com-
pared to countries located centrally in the belt [5].
The carriage prevalence of N. lactamica was compar-
able to that found in a study in Burkina Faso using the
same methodology [30], but significantly higher than in
a recent study in Ethiopia and other African countries,
which defined N. lactamica based on ribosomal protein
L6 gene (rplF) sequencing [32]. The prevalence of N.
lactamica carriage reported in older studies varied greatly
between settings [20, 21, 31, 54], as well as between geo-
graphically nearby areas [55]. The overall age distribution
was consistent with previous studies, except that we found
the highest prevalence in the 1 year olds, whereas most
others report an increasing carriage rate through the first
2 years of life [19, 30, 32, 55, 56]. Contrary to what have
been suggested by others, [19–21, 32], we found no asso-
ciation between the proportion of carriage of N. lactamica
and N. meningitidis. Additionally, the ratio of carriage
prevalence between the two species varied greatly from
kebele to kebele; high N. lactamica carriage prevalence
did not imply low N. meningitidis carriage or vice-versa.
Oropharyngeal swabbing combined with either direct
plating, as used in this study, or short transportation
time of the swab, improves detection of meningococcal
carriage [57]. No false negative isolates were identified
among the presumed non-meningococcal external quality
control samples. We therefore believe the sampling and
sample treatment were good in this study, despite difficult
field conditions. The true carriage prevalence in the
Table 4 Molecular characteristics of meningococcal carriage isolates in 4 kebeles in Arba Minch, Southern Ethiopia (Continued)
F5-9 1 1
P1.7,30-3 F1-31 1 1
F1-7 5 5
P1.7,30-4 F1-7 1 1
P1.7,30-4 F1-7 1 1
P1.7-11,30 F1-21 2 2
F3-69 1 1
F6-6 1 1
P1.7-11,30-2 F1-21 1 1
P1.7-11,30-3 F1-3 1 1
P1.7-2,30 F1-182 2 2
P1.7-2,30-3 F1-7 2 2
P1.7-2,30-6 F1-7 1 1
2075 P1.7,30 F1-113 1 1
P1.7-2,30 F1-153 2 2
F3-28 1 1
P1.7-2,30-3 F1-153 3 3
P1.7-2,30-5 F1-153 1 1
P1.7-54,30 F1-24 1 1
7389 P1.7-2,30 F1-7 1 1
11594 P1.7,30-2 F1-7 1 1
UAb 11587 P1.18-1,3-8 F4-72 1 1
P1.18-11,42-1 F5-102 1 1
11595 P1.18-1,3 F4-72 4 4
11597 P1.22-11,15-25 F1-36 2 2
11624 P1.18-1,3 F4-72 1 1
11638 P1.18-1,3-8 F4-72 1 1
UA 11593 P1.22-1,14 F5-19 1 1
11617 P1.22-11,15-57 F5-7 2 2
ST sequence type, CC clonal complex, n number of isolates, NG non-groupable, UA unassigned to any clonal complex, Neg negative
aKebele: Genta Mechie (A), Zigiti Mechie (B), Gatse (C) and Kolla Shelle (D)
bUA cluster related to ST-11587
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Fig. 6 Phylogenetic tree of meningococcal sequence types (STs) in Arba Minch, Southern Ethiopia. Pie charts indicate the distribution by kebele
and the horizontal bars on the right represent the total number of isolates. The node numbers designate the percentage of bootstrap replications
Bårnes et al. BMC Infectious Diseases  (2016) 16:639 Page 11 of 14
population is, however, likely to be higher than reported,
as sensitivity of swabbing and culture is estimated to be
60–83 % [58]. The use of PCR for direct detection of
meningococci from oropharyngeal swabs, in addition to
culturing, may have increased the number of detected
carriers [59].
Conclusions
No N. meningitidis belonging to serogroup A was de-
tected among 7479 healthy carriers in the Arba Minch
area in Ethiopia in 2014. Thus, the immediate public
health impact of the introduction of the monovalent
serogroup A conjugate vaccine later the same year is not
expected to be measurable as it was in other countries,
where serogroup A circulation was stopped and herd
protection established [26, 27].
N. meningitidis belonging to ST-192 with neither cap-
sule nor FetA expression were most frequently found,
showing that these surface-exposed components are not
required for successful transmission.
Carriage of N. meningitidis and N. lactamica was in-
fluenced by age and geography, even within a small geo-
graphic area.
The presence of epidemic strains assigned to the viru-
lent clonal complexes ST-11 (serogroup W) and ST-181
(serogroup X) highlights the need for multivalent conju-
gate vaccines covering these serogroups.
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